JAMA· 2023Q1
Donanemab in Early Symptomatic Alzheimer Disease
- 2,636citations
- Q1SCImago
- 2023year
Short summary
Donanemab, an antibody targeting amyloid plaques, significantly slowed clinical progression in early symptomatic Alzheimer's disease patients with amyloid and tau pathology over 76 weeks.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Psychiatry and Mental health
Psychiatry and Mental healthMedicine